Brokerages Set UroGen Pharma Ltd. (NASDAQ:URGN) Target Price at $38.20

UroGen Pharma Ltd. (NASDAQ:URGN) has earned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $38.20.

A number of brokerages have commented on URGN. HC Wainwright reduced their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Monday, March 10th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price for the company.

Insider Buying and Selling

In other news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

Institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new stake in shares of UroGen Pharma in the third quarter worth $249,000. Intech Investment Management LLC purchased a new stake in UroGen Pharma in the third quarter valued at $155,000. Charles Schwab Investment Management Inc. raised its stake in shares of UroGen Pharma by 9.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 90,493 shares of the company’s stock valued at $1,149,000 after buying an additional 7,576 shares during the last quarter. FMR LLC lifted its holdings in shares of UroGen Pharma by 575.1% in the 3rd quarter. FMR LLC now owns 23,090 shares of the company’s stock valued at $293,000 after buying an additional 19,670 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after buying an additional 5,890 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Price Performance

NASDAQ URGN opened at $12.02 on Friday. The company has a market cap of $554.05 million, a PE ratio of -3.82 and a beta of 1.12. The firm’s 50 day moving average price is $10.50 and its 200-day moving average price is $11.60. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma has a 52-week low of $9.03 and a 52-week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Sell-side analysts forecast that UroGen Pharma will post -3.12 EPS for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.